Viskase Holdings, Inc.: Board approved and filed Certificate of Designation of Series A-2 Junior Participating Preferred Stock in connection with Section 382 Rights Agreement (effective 2026-05-05).
“In connection with the adoption of the Section 382 Rights Agreement, the Board approved a Certificate of Designation of Series A-2 Junior Participating Preferred Stock of Viskase Holdings, Inc. (the “Certificate of Designation”). The Certificate of Designation was filed with the Secretary of the State of Delaware on May 5, 2026.”
Material Agreements
Viskase Holdings, Inc. entered into Section 382 Rights Agreement with Continental Stock Transfer & Trust Company (effective 2026-05-05).
“On April 30, 2026 (the “Rights Dividend Declaration Date”), the Board of Directors (the “Board”) of Viskase Holdings, Inc. (formerly known as Enzon Pharmaceuticals, Inc.) (the “Company”) adopted a Section 382 Rights Agreement (the “Section 382 Rights Agreement”)”
Craig Pettit was appointed as member of the Board at Viskase Holdings, Inc..
“On April 30, 2026, the Company appointed each of Mr. Thomas D. Davis, the Company’s Chief Executive Officer, and Mr. Craig Pettit to serve as members of the Board to fill the vacancies created by the resignations of Messrs. Peter Shea and Read.”
Thomas D. Davis was appointed as member of the Board at Viskase Holdings, Inc..
“On April 30, 2026, the Company appointed each of Mr. Thomas D. Davis, the Company’s Chief Executive Officer, and Mr. Craig Pettit to serve as members of the Board to fill the vacancies created by the resignations of Messrs. Peter Shea and Read.”
Randolph C. Read resigned as member of the Board at Viskase Holdings, Inc..
“Also, on April 29, 2026, Randolph C. Read notified the Company of his decision to resign as a member of the Board.”
Peter K. Shea resigned as member of the Board of Directors at Viskase Holdings, Inc..
“On April 29, 2026, Peter K. Shea notified the Company of his decision to resign as a member of the Board of Directors (the "Board"), including from his service on the Company’s Audit Committee.”
Material Agreements
Viskase Holdings, Inc. amended Seventh Amendment with certain lenders and Bank of America, N.A., as administrative agent (effective 2026-04-16).
“On April 16, 2026, Viskase Companies, LLC (“Viskase Companies”), a wholly owned subsidiary of Viskase Holdings, Inc., entered into the Seventh Amendment (the “Seventh Amendment”) to its Credit Agreement, dated as of October 9, 2020, by and between Viskase Companies, certain subsidiaries of Viskase Companies, certain lenders party thereto, and Bank of America, N.A., as administrative agent”
Auditor Changes
Viskase Holdings, Inc. engaged Grant Thornton LLP as its auditor.
“pril 14, 2026, the Audit Committee of the Company appointed Grant Thornton LLP (“Grant Thornton”) as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the fiscal year ending”
Auditor Changes
Viskase Holdings, Inc. dismissed EisnerAmper LLP as its auditor.
“was informed on April 15, 2026, that it was dismissed as the Company’s independent registered public accounting firm.”
Governance Changes
Viskase Holdings, Inc.: Eliminated Certificate of Designation for Series A-1 Junior Participating Preferred Stock via Certificate of Elimination.
“the Company filed a Certificate of Elimination (the “ Certificate of Elimination ”) to its Certificate of Incorporation with the Secretary of State of the State of Delaware eliminating from the Certificate of Incorporation all matters set forth in the Certificate of Designation with respect to the Company’s Series A-1 Junior Participating Preferred Stock”
Governance Changes
Viskase Holdings, Inc.: Changed company name to Viskase Holdings, Inc. via Certificate of Amendment to Amended Certificate of Incorporation.
“the Company filed a Certificate of Amendment (the “ Certificate of Amendment ”) to its Amended Certificate of Incorporation (the “ Certificate of Incorporation ”) with the Secretary of State of the State of Delaware to change its name to “Viskase Holdings, Inc.””
M&A Transactions
Viskase Holdings, Inc. underwent a change of control involving Viskase Companies, Inc. for all-stock transaction (closed 2026-03-26).
“On March 26, 2026 (the " Closing Date "), Viskase Holdings, Inc. (formerly known as Enzon Pharmaceuticals, Inc.) (the " Company " or the " Combined Company ") consummated the previously announced transactions pursuant to the Agreement and Plan of Merger, dated as of June 20, 2025, by and among the Company, EPSC Acquisition Corp. (" Merger Sub "), and Viskase Companies, Inc. (" Viskase "), as amended by the First Amendment to the Agreement and Plan of Merger, dated as of October 24, 2025 (as amended, the " Merger Agreement ").”
M&A Transactions
Viskase Holdings, Inc. completed an acquisition involving Viskase Companies, Inc. for all-stock transaction (closed 2026-03-26).
“On March 26, 2026 (the " Closing Date "), Viskase Holdings, Inc. (formerly known as Enzon Pharmaceuticals, Inc.) (the " Company " or the " Combined Company ") consummated the previously announced transactions pursuant to the Agreement and Plan of Merger, dated as of June 20, 2025, by and among the Company, EPSC Acquisition Corp. (" Merger Sub "), and Viskase Companies, Inc. (" Viskase "), as amended by the First Amendment to the Agreement and Plan of Merger, dated as of October 24, 2025 (as amended, the " Merger Agreement ").”
Governance Changes
Viskase Holdings, Inc.: Effected a 1-for-100 reverse stock split by filing Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective March 24, 2026 at 4:30 p.m. Eastern Time (effective 2026-03-24).
“On March 24, 2026, the Company announced that the 1-for-100 reverse stock split (the “ Reverse Stock Split ”), which was previously approved by the Company’s stockholders, will become effective as of 4:30 p.m., Eastern Time, on March 24, 2026 (“ Effective Time ”).”
Material Agreements
Viskase Holdings, Inc. amended Tenth Amendment to Section 382 Rights Agreement with Continental Stock Transfer & Trust Company (effective 2026-03-18).
“On March 18, 2026, Enzon Pharmaceuticals, Inc. (the “ Company ”) entered into the Tenth Amendment to the Section 382 Rights Agreement (the “ Tenth Amendment ”)”
Material Agreements
Viskase Holdings, Inc. amended Ninth Amendment to the Section 382 Rights Agreement with Continental Stock Transfer & Trust Company valued at Extended the Final Expiration Date from noon, New York City time, on March 11, 2026 to noon, New Yor (effective 2026-03-10).
“On March 10, 2026, Enzon Pharmaceuticals, Inc. (the “ Company ”) entered into the Ninth Amendment to the Section 382 Rights Agreement (the “ Ninth Amendment ”), which amends the Section 382 Rights Agreement, dated as of August 14, 2020 (the “ Rights Agreement ”), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent.”
Material Agreements
Viskase Holdings, Inc. amended Eighth Amendment to the Section 382 Rights Agreement with Continental Stock Transfer & Trust Company (effective 2026-02-27).
“On February 27, 2026, Enzon Pharmaceuticals, Inc. (the “ Company ”) entered into the Eighth Amendment to the Section 382 Rights Agreement (the “ Eighth Amendment ”), which amends the Section 382 Rights Agreement, dated as of August 14, 2020 (the “ Rights Agreement ”), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent.”
Material Agreements
Viskase Holdings, Inc. entered into Sixth Amendment with Continental Stock Transfer & Trust Company (effective 2025-12-23).
“On December 23, 2025, Enzon Pharmaceuticals, Inc. (the “ Company ”) entered into the Sixth Amendment to the Section 382 Rights Agreement (the “ Sixth Amendment ”), which amends the Section 382 Rights Agreement, dated as of August 14, 2020 (the “ Rights Agreement ”), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent.”
Stephen T. Wills was appointed as Director at Viskase Holdings, Inc..
“On January 7, 2025, the Board of Directors (the “Board”) of Enzon Pharmaceuticals, Inc. (the “Company”) approved an increase in the number of directors on the Board to four and appointed Stephen T. Wills as a director, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.